INTRODUCTION
============

The treatment of benign prostatic hyperplasia (BPH) has undergone enormous alterations in recent years. In 1926, transurethral resection of the prostate (TURP) was presented by McCarthy, leading to a paradigm shift in surgery for BPH. Since that time, TURP has been considered the standard surgical treatment of small to moderate-size obstructive BPH. The American Urological Association guidelines define TURP as the ''gold standard'' surgical treatment for BPH \[[@b1-inj-1732640-320]-[@b3-inj-1732640-320]\]. Holmium laser enucleation (HoLEP) was developed in the 1990s as a surgical treatment for BPH that is more effective and safer than laser vaporization and traditional resection techniques. HoLEP has become the novel standard for the surgical treatment of BPH because it is effective while being less invasive and having a low incidence of complications. The effectiveness and safety of HoLEP to treat BPH are well known; recently, this technique has been used on prostates of various sizes \[[@b3-inj-1732640-320]\]. Many studies have compared the effectiveness of HoLEP and TURP in terms of improvement in voiding symptoms, maximal flow rate (Qmax), postvoid residual volume (PVR), the International Prostate Symptom Score (IPSS), and complications. Most studies have reported improved postoperative outcomes and the occurrence of fewer complications when HoLEP was used than when TURP was performed.

Traditionally, surgical treatment was not recommended for patients with BPH combined with detrusor underactivity (DU) due to limited improvement in voiding symptoms and reduced postoperative satisfaction compared to patients with normal detrusor contractility. However, recent studies have shown surgical treatment to be effective in improving voiding symptoms and efficiency in patients diagnosed with BPH and DU \[[@b4-inj-1732640-320]\], but limited comparative data have been published regarding the efficacy and safety of HoLEP and TURP in patients with DU. We therefore retrospectively compared the perioperative and postoperative clinical outcomes of HoLEP and TURP procedures performed by a single surgeon for the surgical treatment of patients who were diagnosed with BPH and DU.

MATERIALS AND METHODS
=====================

We retrospectively analyzed the medical charts of patients diagnosed with BPH and DU who underwent surgical treatment (TURP or HoLEP) at Kyungpook National University Hospital between May 2010 and May 2015. A total of 352 patients presenting with voiding symptoms due to BPH were surgically treated by a single surgeon during this period. TURP was performed between May 2010 and April 2012. Since May 2012, when holmium laser instrument equipment was installed, HoLEP has been performed in most patients, except in the event of a technical problem involving the equipment. The inclusion criteria were: (1) detrusor pressure at Qmax (PdetQmax)\<40 cm H~2~O as measured by a pressure flow study, and (2) medication with α-receptor blockers or 5α-reductase inhibitors for at least 6 months before surgery. Patients diagnosed with a current urinary tract infection, bladder cancer, or prostate cancer were excluded. After applying these exclusion criteria, 56 patients who underwent surgical management for symptomatic BPH with DU were included in the present study.

DU, or underactive bladder, was defined as late emptying of the bladder, decreased contractility, and failure to empty the bladder in the normal time span \[[@b5-inj-1732640-320]\]. In this study, we defined DU as a value of PdetQmax\<40 cm H~2~O observed in a preoperative pressure flow study.

Indications for the surgical management of BPH included lower urinary tract symptoms refractory to other medical therapies, or a history of acute urinary retention, bladder stones, gross hematuria, or renal insufficiency secondary to BPH. All patients underwent an initial review of their past medical history, followed by a physical examination, serum prostate-specific antigen measurement, urinalysis, assessment of the IPSS and the quality of life (QoL) score, transrectal ultrasonography to measure the volume of the prostate, uroflowmetry to measure the PVR, and a pressure-flow urodynamic assessment.

The instrumentation for HoLEP included 550-nm end-firing flexible quartz and a continuous-flow resectoscope consisting of a 26-Fr outer sheath and an inner rotating sheath. The device used for HoLEP was the Versapulse Powersuite holmium laser (Lumenis Inc., Tel Aviv, Israel). HoLEP was performed using the standard technique described by Gilling et al. \[[@b6-inj-1732640-320]\]. The procedure was performed with a frequency of 40 Hz and 2.0 J of power. Normal saline was used for irrigation. After a cystoscopic exam, incisions were made at the 5-o'clock and 7-o'clock aspect to enucleate the median lobe of the prostate. Another incision was made at the 12-o'clock aspect to enucleate the lateral lobes of the prostate. A defocused laser beam was used to control points of bleeding. The lobes were then delivered by a VersaCut Morcellator System (Lumenis Inc.) depending upon the size of the enucleated tissue. The specimen retrieved was weighed inside the operating room and sent for histopathologic analysis.

Conventional TURP is a monopolar technique using a high-frequency current, with a maximum cutting power of 200 W \[[@b7-inj-1732640-320],[@b8-inj-1732640-320]\]. However, bipolar TURP using saline as the irrigation fluid has been introduced \[[@b9-inj-1732640-320]\]. High-frequency energy, up to 160 W, flows through normal saline, resulting in prostatic adenoma resection at a lower temperature than traditional monopolar TURP, thereby theoretically reducing the thermal tissue damage. At our center, TURP was performed using the standard bipolar technique with saline as the irrigation fluid. The bipolar devices used were a Gyrus 26-Fr resectoscope (Karl Storz GmbH & Co. KG, Tuttlingen, Germany) with a cutting current of 120--160 W and a coagulating power of 60--80 W. Normal saline was used as the intraoperative irrigation fluid. TURP chips were removed using an Ellick evacuator.

The IPSS, Qmax, and PVR were investigated to analyze the postoperative outcomes. Total operation time, the resected volume of the prostate, loss of hemoglobin, catheterization time, length of hospital stay, and postoperative complications were analyzed in both groups. Patients were instructed to stop taking medication at the first follow-up visit 2 weeks after surgery, at which point the decision to prescribe an α-blocker or anticholinergic medication was made according to the patient\`s symptoms, IPSS, and uroflowmetry results. In addition, postoperative outcomes were assessed 6 months after BPH surgery. The analysis focused on the voiding symptom score, uroflowmetry, and risk of surgical complications. Differences between preoperative and postoperative IPSS, Qmax, and PVR were compared in both groups.

Data are expressed as mean±standard deviation. The Student t-test was used to compare differences in baseline patient characteristics, perioperative outcomes, and postoperative outcomes between the 2 groups. Postoperative complications and the medications required after surgery were compared using the chi-square test. Statistical analysis was performed using IBM SPSS ver. 18.0 (IBM Co., Armonk, NY, USA), and P-values \<0.05 were considered to indicate statistical significance.

The Institutional Review Board of the Kyungpook National University School of Medicine approved our study protocol (approval number: KNUH 2016-04-004-001).

RESULTS
=======

Fifty-six patients were initially included in the analysis: 24 in the HoLEP group and 32 in the TURP group. The mean age of the patients in the HoLEP and TURP groups was 66.9±7.0 and 71.4±5.6 years, respectively (P=0.274); the mean prostate volume was 58.0±17.8 and 54.2±13.9 mL, respectively (P=0.386); and the PdetQmax was 34.4±6.5 and 33.1±10.0 cm H~2~O, respectively (P=0.575). No significant differences in the preoperative prostate volume, Qmax, or PdetQmax were observed between the groups ([Table 1](#t1-inj-1732640-320){ref-type="table"}). The operative time was significantly shorter in the TURP group than in the HoLEP group. The weight of the resected prostate gland was significantly greater in the HoLEP group than in the TURP group. The mean operative time was 90.2±15.0 and 78.8±23.9 minutes (P=0.033) in the HoLEP and TURP groups, respectively, and the mean resected volume was 39.0±17.7 and 25.0±7.8 g, respectively (P=0.001). Blood loss, catheterization time, and the length of the hospital stay were significantly lower in the HoLEP group. The hemoglobin loss was 1.2±0.6 and 1.7±0.9 g/dL (P=0.015) in the HoLEP and TURP groups, respectively ([Table 2](#t2-inj-1732640-320){ref-type="table"}). After catheter removal, 1 patient in the TURP group (3.1%) required temporary catheter reinsertion due to acute urinary retention. One patient (3.1%) received a blood transfusion due to excessive gross hematuria ([Table 3](#t3-inj-1732640-320){ref-type="table"}).

At the 6-month postoperative follow-up, patients in the HoLEP group demonstrated higher Qmax and lower PVR values than those in the TURP group. The Qmax and PVR were 18.5±7.1 and 13.2±6.5 mL/sec, respectively (P=0.005), and 13.75±41.7 and 45.0±57.6 mL, respectively (P=0.022) in the HoLEP and TURP groups. Patients showed overall improvements in the IPSS. The HoLEP group showed significantly greater improvement in the total IPSS, the IPSS voiding symptom score, and the IPSS storage symptom score than the TURP group. The changes in the total IPSS and IPSS voiding symptom score were 8.0±7.4 and 3.2±1.8, respectively (P=0.005), and 6.5±5.8 and 2.3±1.4, respectively (P=0.002), in the HoLEP and TURP groups. The change in the IPSS storage symptom score was also greater in the HoLEP group than in the TURP group, but this difference was not statistically significant ([Table 4](#t4-inj-1732640-320){ref-type="table"}) ([Fig. 1](#f1-inj-1732640-320){ref-type="fig"}). Two patients in the TURP group developed urethral stricture (6.3%), and 1 patient in the HoLEP group showed persistent stress urinary incontinence (4.2%) ([Table 3](#t3-inj-1732640-320){ref-type="table"}).

Postoperatively, 56.6% of patients in the TURP group required α-blocker medications and 28.1% required anticholinergic medications. However, in the HoLEP group, 12.5% of patients required α-blocker medications and 16.7% of patients required anticholinergic medications ([Fig. 2](#f2-inj-1732640-320){ref-type="fig"}).

DISCUSSION
==========

Ahyai et al. \[[@b10-inj-1732640-320]\] performed a meta-analysis of 23 randomized controlled trials comparing TURP, HoLEP, open prostatectomy (OP), and photoselective vaporization of the prostate in 2,245 patients. The authors found that HoLEP was superior to TURP in terms of IPSS and postoperative Qmax; moreover, HoLEP was the only surgical treatment for which reoperation was not required for the resection of a prostate adenoma within 5 years. Some researchers have argued that HoLEP has a significantly longer operative time compared to TURP. However, Ahyai et al. \[[@b10-inj-1732640-320]\] reported that the mean resection rate of prostate tissue (g/min) for HoLEP and TURP was not significantly different (0.52 g/min vs. 0.57 g/min). According to that study, both surgical procedures were equally time-efficient. HoLEP was associated with fewer postoperative complications than TURP, and post-transurethral resection syndrome has never been reported with HoLEP, even for large prostates weighing hundreds of grams \[[@b10-inj-1732640-320]\]. Yin et al. \[[@b11-inj-1732640-320]\] published a meta-analysis comparing 6 randomized controlled trials comparing HoLEP to TURP. HoLEP was significantly superior to TURP in terms of both Qmax and IPSS at 1-year postoperative follow-up visits. Furthermore, HoLEP patients benefited from less intraoperative bleeding, a shorter catheterization time, shorter hospital stays, and lower transfusion rates. Gilling et al. \[[@b12-inj-1732640-320]\] reported postoperative outcomes from prospective cohorts followed for 92 months. They reported that HoLEP, on average, resulted in greater resected volume of the prostate, shorter catheterization times, and shorter hospital stays. Furthermore, patients who underwent HoLEP exhibited greater reductions in voiding symptoms and greater improvements in postoperative Qmax when compared to preoperative values. No patient in the HoLEP group required reoperation for the resection of prostate adenoma, compared to an 18% reoperation rate in the TURP group \[[@b12-inj-1732640-320]\]. Naspro et al. \[[@b13-inj-1732640-320]\] found that patients who underwent HoLEP had almost equivalent functional outcomes, but a lower transfusion rate, shorter catheterization times, and shorter hospital stays than those who underwent OP. Many other studies have also shown shorter hospital stays and urethral catheterization times with HoLEP. The preoperative and postoperative outcomes of these studies have demonstrated that HoLEP is more effective than TURP. Those findings are similar to the findings of our study. The results concerning the necessity of reoperation provide clear evidence that HoLEP is an appropriate alternative to TURP and OP.

DU is a common cause of urinary bladder dysfunction, although it is under-researched and poorly understood. The clinical features of unsuitable bladder emptying may arise because of DU but may also be due to bladder outflow obstruction (BOO). It is often difficult to differentiate DU from BOO without invasive pressure flow studies. Clinical evaluation is further limited by the subjective interpretation of the effects of diminished strength, decreased length of contraction, and prolonged emptying time. Nevertheless, the distinction between DU and BOO provides a useful conceptual framework within which to define the functional abnormality underlying the clinical presentation of patients who may have variable symptoms, because it is recognized that the "bladder is an unreliable witness." \[[@b14-inj-1732640-320]\].

Most studies of TURP have not evaluated its durability or efficacy, although morbidity has often been reported to improve. In men with enlarged prostates, treatment alternatives are even more limited. The characteristics of the holmium laser wave length determine its versatility and provide an endoscopic alternative to both TURP and OP when used for enucleation \[[@b15-inj-1732640-320],[@b16-inj-1732640-320]\]. Several studies have found that BPH patients with DU had less favorable symptomatic and clinical outcomes after transurethral prostate surgery. Thomas et al. \[[@b17-inj-1732640-320]\] reported that no advantages in terms of long-term symptomatic improvement or urodynamic findings were found to have arisen from TURP in BPH patients with DU. TURP in BPH patients with DU is associated with a smaller long-term decrease in BOO, showing a reduction in voiding pressure with no significant change in voiding flow rate. It was not associated with changes in detrusor contractility. Subjective and objective changes in symptoms were not found. Additionally, patients without urodynamic obstructions showed no statistically significant postoperative differences compared to the preoperative data \[[@b18-inj-1732640-320]\]. However, other recent studies have reported that transurethral BPH surgery in patients with DU resulted in significantly improved QoL and voiding symptoms. Thus, the effects of transurethral prostate surgery in patients with DU are still poorly understood. Despite the many controversies, few studies have compared the surgical outcomes of TURP versus HoLEP for the treatment of BPH with DU. In the present study, we showed that HoLEP was superior to TURP with regard to postoperative Qmax, PVR, symptomatic improvement, and QoL. It seems that when patients with DU underwent transurethral surgery, the most significant effect was related to the removal of prostatic obstruction. With the resolution of outflow obstruction, voiding is possible with low bladder detrusor muscle contractility, resulting in postoperative benefits in urinary symptoms and reduced PVR. Both the TURP and HoLEP groups showed improvements in voiding symptoms and in other postoperative data, including QoL, IPSS, Qmax, and PVR. Therefore, both TURP and HoLEP can be effective in patients with BPH and DU. However, our data demonstrated that patients in the HoLEP group showed significantly greater improvements than patients in the TURP group in the other parameters, with the exception of operative time. Possible reasons for the longer operative time in the HoLEP group could be the slow vaporization by holmium laser energy or the additional time required for adenoma morcellation. Similar findings have been previously reported by Kuntz et al. \[[@b19-inj-1732640-320]\] In this study, although the overall operative time was longer with HoLEP than TURP, statistical significance was not observed when dividing the weight of resected prostate tissue by time in an analysis of tissue removal efficiency. Additionally, the hemostatic nature of the holmium laser provides many perioperative and postoperative advantages compared to TURP, including a lower rate of complications, less blood loss, reduced catheterization time, and shorter hospitalization.

One of the major and most common complications of TURP is the risk of bleeding. A recent review by Rassweiler et al. \[[@b8-inj-1732640-320]\] evaluating TURP complications reported that hemorrhage was the most common complication, despite recent advances in resection techniques and technology. Decreased postoperative bleeding has been one of the main advantages of HoLEP.

In our analysis, all patients stopped taking 5α-reductase inhibitors postoperatively, but some patients in both groups required α-blocker or anticholinergic medications. It was more common for patients to require medication in the TURP group than in the HoLEP group, which was ascribable to the improved efficiency of obstruction removal using HoLEP. In this study, all procedures were performed by a highly experienced single surgeon. Consequently, the adenomas were resected sufficiently in all procedures. However, we found that greater quantities of adenoma were resected in the HoLEP procedures. This is thought to be due to differences in the surgical technique of HoLEP, which enables anatomically based resection. More effective removal of adenomas is expected to lead to better outcomes after HoLEP.

Certain limitations of this study should be considered. This study lacked long-term follow-up, and was retrospective in design. The analysis was limited to a small number of patients because of the rarity of patients with both BPH and DU undergoing surgical treatment. Future prospective studies are needed to obtain a more detailed analysis of this patient population, including outcomes related to prostate size and sexual function. In addition, a study including BPH patients without DU will be necessary. The findings of this study warrant further validation in a randomized controlled study with a larger number of patients and longer follow-up in order to evaluate HoLEP as the new standard procedure for the surgical treatment of BPH with DU.

In conclusion, over the course of short-term follow-up, HoLEP and TURP were found to effectively improve postoperative symptom-related outcomes in BPH patients with DU. HoLEP showed better efficacy than TURP in improving voiding symptoms, Qmax, PVR, medication requirements, and in minimizing postoperative complications.
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![Variation in the total IPSS, the voiding subscore, and the storage subscore. IPSS, International Prostate Symptom Score. HoLEP, holmium laser enucleation of the prostate; TURP, transurethral resection of the prostate.](inj-1732640-320f1){#f1-inj-1732640-320}

![Number of patients who required medications after surgery. Postoperatively, α-blocker medications were required by 56.6% and 12.5% (P=0.001) of the patients in the TURP and HoLEP groups, respectively. Anticholinergics were required by 28.1% and 16.7% (P=0.315) of the patients in the TURP and HoLEP groups, respectively. HoLEP, holmium laser enucleation of the prostate; TURP, transurethral resection of the prostate.](inj-1732640-320f2){#f2-inj-1732640-320}

###### 

Comparison of baseline patient characteristics between the HoLEP and TURP groups

  Characteristic                                                           HoLEP (n=24)    TURP (n=32)     P-value
  ------------------------------------------------------------------------ --------------- --------------- ---------
  Age (yr)                                                                 66.9 ± 7.0      71.4 ± 5.6      0.274
  Prostate volume (mL)^[a)](#tfn1-inj-1732640-320){ref-type="table-fn"}^   58.0 ± 17.8     54.2 ± 13.9     0.386
  Preoperative IPSS                                                                                        
   Total                                                                   18.7 ± 6.2      15.7 ± 7.5      0.120
   Voiding subscore                                                        11.1 ± 4.6      9.0 ± 4.8       0.104
   Storage subscore                                                        7.5 ± 3.4       6.7 ± 3.3       0.348
  Maximal flow rate (mL/sec)                                               7.4 ± 3.0       6.3 ± 3.9       0.212
  Postvoid residual urine volume (mL)                                      113.0 ± 128.0   151.0 ± 118.0   0.258
  PdetQmax (cm H~2~O)                                                      34.4 ± 6.5      33.1 ± 10.0     0.575

Values are presented as mean±standard deviation.

HoLEP, holmium laser enucleation of the prostate; TURP, transurethral resection of the prostate; IPSS, International Prostate Symptom Score; PdetQmax, detrusor pressure at maximal flow rate.

Prostate volume was measured by transrectal ultrasonography.

###### 

Comparison of perioperative surgical outcomes between the HoLEP and TURP groups

  Variable                              HoLEP (n=24)   TURP (n=32)   P-value
  ------------------------------------- -------------- ------------- ----------
  Resected volume (g)                   39.0 ± 17.7    25.0 ± 7.8    0.001
  Operative time (min)                  90.2 ± 15.0    78.8 ± 23.9   0.033
  Hemoglobin loss (g/dL)                1.2 ± 0.6      1.7 ± 0.9     0.015
  Postoperative catheterization (day)   3.3 ± 0.6      4.5 ± 1.0     \< 0.001
  Hospital stay (day)                   4.3 ± 0.6      5.5 ± 1.0     \< 0.001

Values are presented as mean±standard deviation.

HoLEP, holmium laser enucleation of the prostate; TURP, transurethral resection of the prostate; IPSS, International prostate symptom score.

###### 

Postoperative complications at 6 months

  Adverse event                 HoLEP (n=24)   TURP (n=32)   P-value
  ----------------------------- -------------- ------------- ---------
  Blood transfusion             0 (0)          1 (3.1)       0.382
  Recatheterization             0 (0)          1 (3.1)       0.382
  Urethral stricture            0 (0)          2 (6.3)       0.212
  Stress urinary incontinence   1 (4.2)        0 (0)         0.244
  Total                         1 (4.2)        4 (12.5)      0.279

Values are presented as number (%).

HoLEP, holmium laser enucleation of the prostate; TURP, transurethral resection of the prostate.

###### 

Comparison of postoperative voiding status between the HoLEP and TURP groups

  Variable                              HoLEP (n=24)   TURP (n=32)   P-value
  ------------------------------------- -------------- ------------- ---------
  Postoperative IPSS                                                 
   Total                                10.7 ± 5.4     12.5 ± 7.6    0.307
   Voiding subscore                     4.7 ± 3.7      6.8 ± 4.7     0.078
   Storage subscore                     6.1 ± 3.5      5.8 ± 3.2     0.709
  Maximal flow rate (mL/sec)            18.5 ± 7.1     13.2 ± 6.5    0.005
  Postvoid residual urine volume (mL)   13.75 ± 41.7   45.0 ± 57.6   0.022
  ΔTotal IPSS                           8.0 ± 7.4      3.2 ± 1.8     0.005
  ΔIPSS Voiding subscore                6.5 ± 5.8      2.3 ± 1.4     0.002
  ΔIPSS Storage subscore                1.5 ± 3.1      0.9 ± 1.2     0.445

Values are presented as mean±standard deviation.

HoLEP, holmium laser enucleation of the prostate; TURP, transurethral resection of the prostate; IPSS, International prostate symptom score; IPSS, International Prostate Symptom Score; Δ, Difference between preoperative score and postoperative score.
